Marc R. Radke
YOU?
Author Swipe
View article: Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series
Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series Open
Recurrent ovarian cancer (OC) is challenging to detect early using current methods like CA-125 and imaging. Circulating tumor DNA (ctDNA) may improve disease monitoring. Here, we assess the real-world clinical utility of serial ctDNA analy…
View article: HRDPath: An Explainable Multi-Model Deep Learning Architecture for Predicting Homologous Recombination Deficiency from Histopathology Images
HRDPath: An Explainable Multi-Model Deep Learning Architecture for Predicting Homologous Recombination Deficiency from Histopathology Images Open
Homologous recombination deficiency (HRD) is a critical biomarker for guiding treatment decisions in high-grade serous tubo-ovarian carcinoma (HGSOC), a cancer with few reliable biomarkers. However, existing genomic-based tests for HRD are…
View article: Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions
Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions Open
View article: Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models
Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models Open
View article: Abstract #22: Impact of somatic TP53 mutation type on benefit from bevacizumab in patients with ovarian cancer, a secondary analysis of NRG/GOG-0218
Abstract #22: Impact of somatic TP53 mutation type on benefit from bevacizumab in patients with ovarian cancer, a secondary analysis of NRG/GOG-0218 Open
View article: BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance Open
View article: TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations
TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations Open
View article: The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial Open
View article: NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma Open
Background Our preclinical work revealed tumour hypoxia induces homologous recombination deficiency (HRD), increasing sensitivity to Poly (ADP-ribose) polymerase inhibitors. We aimed to induce tumour hypoxia with ramucirumab thereby sensit…
View article: Constitutional BRCA1 and RAD51C methylation associated with corresponding gene methylation in BRCA wildtype ovarian cancer (156)
Constitutional BRCA1 and RAD51C methylation associated with corresponding gene methylation in BRCA wildtype ovarian cancer (156) Open
View article: 21 Hormone replacement therapy utilization over time following risk-reducing salpingo-oophorectomy in premenopausal patients at high risk for ovarian cancer
21 Hormone replacement therapy utilization over time following risk-reducing salpingo-oophorectomy in premenopausal patients at high risk for ovarian cancer Open
Objectives: Bilateral salpingo-oophorectomy (BSO) is recommended to reduce the risk of ovarian cancer in patients with high-risk germline mutations, but the resultant surgical menopause can lead to detrimental health effects and impact qua…
View article: <i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer
<i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer Open
Poly(ADP-ribose) polymerase inhibitors (PARPis) have changed the treatment paradigm in breast cancer gene ( BRCA )–mutant high-grade serous ovarian carcinoma (HGSC). However, most patients eventually develop resistance to PARPis, highlight…
View article: Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays
Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays Open
PURPOSE Homologous recombination DNA repair deficiency (HRD) is a therapeutic biomarker for sensitivity to platinum and poly(ADP-ribose) polymerase inhibitor therapies in breast and ovarian cancers. Several molecular phenotypes and diagnos…
View article: Supplementary Tables 1-6 from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer
Supplementary Tables 1-6 from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer Open
Table S1. Clinical patient informationTable S2. Duplex Sequencing gene targetsTable S3. Custom probes for hotspotsTable S4. Mutation Frequency and Mutation Burden by patient and geneTable S5. Codons most frequently mutated in ovarian cance…
View article: Data from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer
Data from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer Open
Current screening methods for ovarian cancer have failed to demonstrate a significant reduction in mortality. Uterine lavage combined with TP53 ultradeep sequencing for the detection of disseminated ovarian cancer cells has emerged …
View article: Supplementary Methods from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer
Supplementary Methods from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer Open
Supplementary Methods
View article: Data from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer
Data from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer Open
Current screening methods for ovarian cancer have failed to demonstrate a significant reduction in mortality. Uterine lavage combined with TP53 ultradeep sequencing for the detection of disseminated ovarian cancer cells has emerged …
View article: Supplementary Tables 1-6 from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer
Supplementary Tables 1-6 from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer Open
Table S1. Clinical patient informationTable S2. Duplex Sequencing gene targetsTable S3. Custom probes for hotspotsTable S4. Mutation Frequency and Mutation Burden by patient and geneTable S5. Codons most frequently mutated in ovarian cance…
View article: Supplementary Figures 1-11 from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer
Supplementary Figures 1-11 from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer Open
S1. Experimental designS2. Association between the variant allele frequency (VAF) of tumor mutations identified in uterine lavage with stage of the ovarian cancer (A) and preoperative CA-125 level (B)S3. Gene distribution of the largest mu…
View article: Supplementary Figures 1-11 from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer
Supplementary Figures 1-11 from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer Open
S1. Experimental designS2. Association between the variant allele frequency (VAF) of tumor mutations identified in uterine lavage with stage of the ovarian cancer (A) and preoperative CA-125 level (B)S3. Gene distribution of the largest mu…
View article: Supplementary Methods from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer
Supplementary Methods from Uterine Lavage Identifies Cancer Mutations and Increased <i>TP53</i> Somatic Mutation Burden in Individuals with Ovarian Cancer Open
Supplementary Methods
View article: Table S2 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Table S2 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
Table S2 shows data concerning the association between baseline characteristics and presence of BRCA reversion mutations in pretreatment circulating cell-free DNA
View article: Table S1 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Table S1 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
Table S1 is an Excel sheet that provides a detailed listing of primary BRCA and TP53 mutations as well as BRCA reversion mutations detected in pretreatment and postprogression circulating cell-free DNA and tumor biopsy samples
View article: Table S1 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Table S1 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
Table S1 is an Excel sheet that provides a detailed listing of primary BRCA and TP53 mutations as well as BRCA reversion mutations detected in pretreatment and postprogression circulating cell-free DNA and tumor biopsy samples
View article: Data from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Data from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA re…
View article: Data from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Data from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that restore protein function. To estimate the prevalence of BRCA re…
View article: Figures S1-S8 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Figures S1-S8 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
Figure S1 shows a consort diagram of patients with pretreatment and postprogression circulating cell-free DNA samples sequenced; Figure S2 shows a bar graph showing that a significantly lower level of the serum marker CA-125 was found at s…
View article: Figures S1-S8 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Figures S1-S8 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
Figure S1 shows a consort diagram of patients with pretreatment and postprogression circulating cell-free DNA samples sequenced; Figure S2 shows a bar graph showing that a significantly lower level of the serum marker CA-125 was found at s…
View article: Table S3 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Table S3 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
Table S3 shows a summary of BRCA reversion mutations detected in postprogression circulating cell-free DNA
View article: Table S3 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Table S3 from <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Open
Table S3 shows a summary of BRCA reversion mutations detected in postprogression circulating cell-free DNA